autologous endothelial progenitor cells

Cell therapyexperimental

Clinical trial activity

5 trials · 11 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0

Earliest trial started Nov 1, 2011 (NCT01468064)

Timeline

2010s

  1. Jan 1, 2011

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2017

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetTissue restoration

    Tissue restoration

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • autologous endothelial progenitor cells

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05459441Early Phase 1 (Phase 1)Jan 1, 2022Fudan University, Ningxia Medical University
NCT03001414Phase 2Apr 1, 2017Northern Therapeutics, University of Ottawa
NCT01886118N/AMar 31, 2013clinique ovo
NCT02474381N/ADec 1, 2012Huazhong University of Science and Technology, Nanjing Medical University
NCT01468064Phase 1/Phase 2 (Phase 2)Nov 1, 2011Cellonis Biotechnology Co. Ltd., Guangzhou Medical University, Second People's Hospital of Nanhai District of Foshan, Southern Medical University
Showing 5 of 5 trials
Page 1 / 1

Organizations

Research & Development (11)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Cellonis Biotechnology Co. Ltd.For profit1012011
clinique ovoAcademic/Hospital1112013
Fudan UniversityAcademic/Hospital1012022
Guangzhou Medical UniversityAcademic/Hospital1012011
Huazhong University of Science and TechnologyAcademic/Hospital1112012
Nanjing Medical UniversityAcademic/Hospital1012012
Ningxia Medical UniversityAcademic/Hospital1112022
Northern TherapeuticsFor profit1112017
Second People's Hospital of Nanhai District of FoshanAcademic/Hospital1012011
Southern Medical UniversityAcademic/Hospital1112011
University of OttawaAcademic/Hospital1012017
11 organizations
Page 1 / 1